Indian Pharmaceutical Market Expected to Maintain Double-Digit Growth Momentum
The Indian Pharmaceutical Market (IPM) is projected to sustain its double-digit growth, with May 2026 marking the sixth consecutive month of over 12% monthly expansion, according to brokerage firm Equirus. Growth is driven by strong volume increases, price adjustments, and new introductions across therapies. Chronic therapies led with a 14.6% growth, while acute therapies also improved to 8.3%. Demand was broad-based, with nine of ten key therapy categories growing in double digits, including cardiac, anti-diabetic, and respiratory segments.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 100%, Right 0%). Overall sentiment is positive (75/100). Lens Score 30/100 — low public interest.
Outlets analysed (first-hand measurement by TBN's Bias Engine):
- economictimes— balanced framing, positive sentiment
- thetribune— balanced framing, positive sentiment
AI Analysis
The articles present a primarily economic and industry-focused perspective without political framing. They rely on data and analysis from a brokerage firm, Equirus, emphasizing market performance and growth drivers. No political viewpoints or partisan interpretations are evident, focusing instead on factual reporting of pharmaceutical market trends.
The tone across the articles is positive and optimistic, highlighting sustained growth and strong demand in the pharmaceutical sector. The coverage emphasizes robust performance indicators and broad-based expansion, reflecting confidence in the market's trajectory without critical or negative commentary.
How 2 sources covered this story
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.